

  
Signature

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Wahl <i>et al.</i>	Confirmation No.:	1873
ApplicationNo.:	10/632,151	Art Unit:	1644
Filed:	July 30, 2003	Examiner:	Ron Schwadron
For:	ANTI-CD20 ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS	Attorney Docket No:	0020-00211US

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES**

**AND**

**STATEMENTS UNDER 37 C.F.R. § 1.821(f); § 1.821(g); and § 1.825(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

This paper is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice") mailed August 28, 2007 in connection with the above-identified application.

Submitted concurrently herewith is a substitute computer readable form (CRF) copy of the Sequence Listing in the form of a text file (.txt) in compliance with 37 CFR § 1.821(e) and a substitute paper copy of the Sequence Listing in accordance with 37 CFR § 1.821(c).

**Amendments to the Specification** begin on page 2 of this paper.

**Remarks** begin on page 3 of this paper.